Effects of Injectable Solutions on the Quality of Monocyte-Derived Dendritic Cells for Immunotherapy

Autor(es)

Da Silva, Lais Teodoro ; Tiyo, Bruna Tiaki ; Mota, Silvia de Jesus ; Ortega, Marina Mazzilli ; Schmitz, Gabriela Justamante Handel ; Taniwaki, Noemi Nosomi ; Nishina, Gislene Mitsue Namiyama ; Duarte, Alberto Jose da Silva ; Oshiro, Telma Miyuki

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF IMMUNOLOGY RESEARCH; v. 2024, p. 11-pg., 2024-06-07.

Resumo

Therapeutic vaccines based on monocyte-derived dendritic cells have been shown to be promising strategies and may act as complementary treatments for viral infections, cancers, and, more recently, autoimmune diseases. Alpha-type-1-polarized dendritic cells (aDC1s) have been shown to induce type-1 immunity with a high capacity to produce interleukin-12p70 (IL-12p70). In the clinical use of cell-based therapeutics, injectable solutions can affect the morphology, immunophenotypic profile, and viability of cells before delivery and their survival after injection. In this sense, preparing a cell suspension that maintains the quality of aDC1s is essential to ensure effective immunotherapy. In the present study, monocytes were differentiated into aDC1s in the presence of IL-4 and GM-CSF. On day 5, the cells were matured by the addition of a cytokine cocktail consisting of IFN-alpha, IFN-gamma, IL-1 beta, TNF-alpha, and Poly I:C. After 48 hr, mature aDC1s were harvested and suspended in two different solutions: normal saline and Ringer's lactate. The maintenance of cells in suspension was evaluated after 4, 6, and 8 hr of storage. Cell viability, immunophenotyping, and apoptosis analyses were performed by flow cytometry. Cellular morphology was observed by electron microscopy, and the production of IL-12p70 by aDC1s was evaluated by ELISA. Compared with normal saline, Ringer's lactate solution was more effective at maintaining DC viability for up to 8 hr of incubation at 4 or 22 degrees C. (AU)

• Processo FAPESP: 19/24849-1 - Delivery de antígenos de HIV associados a nanopartículas: potencial aplicação na imunoterapia anti-HIV com células dendríticas derivadas de monócitos
• Beneficiário: Bruna Tiaki Tiyo
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 23/11990-3 - Produção e caracterização de células dendríticas polarizantes aDC1 para aplicação em protocolo clínico de imunoterapia anti-HIV
• Beneficiário: Laís Teodoro da Silva
• Modalidade de apoio: Bolsas no Brasil - Programa Capacitação - Treinamento Técnico
• Processo FAPESP: 18/12460-0 - Produção e caracterização de células dendríticas polarizantes aDC1 para protocolo clínico de imunoterapia anti-HIV
• Beneficiário: Laís Teodoro da Silva
• Modalidade de apoio: Bolsas no Brasil - Pós-Doutorado
• Processo FAPESP: 14/50489-9 - O timo humano: desenvolvimento e doenças
• Beneficiário: Magda Maria Sales Carneiro-Sampaio
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 16/25212-9 - Vacina terapêutica baseada em células dendríticas aDC1 e vírus autólogo inativado visando o controle viral de indivíduos infectados pelo HIV-1 em interrupção de terapia antirretroviral
• Beneficiário: Alberto José da Silva Duarte
• Modalidade de apoio: Auxílio à Pesquisa - Temático